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Mitochondria are crucial in cell life, as they are the main
intracellular source of energy, and have a main role in cell
death as they contain molecules able to trigger apoptosis.
However, mitochondria can also release molecules called
‘damage-associated molecular patterns’ (DAMPs) that trigger
a potent innate immune response and cause inflammation
through the engagement of the Toll-like receptors (TLR).
During human immunodeficiency virus (HIV) infection, a
proinflammatory status is present that is not completely
explained by the activity of the virus per se, or by the effective
immune response against the virus. However, the presence
of significant amounts of DAMPs of mitochondrial origin,
such as extracellular plasmatic mtDNA, in the peripheral
blood of subjects with HIV infection suggests that part of
the inflammation typical of such infection could be because
of the activity of these molecules, and thus opens new
therapeutic perspectives.
Mitochondria are intracellular organelles involved in a wide
range of processes, as they are the main source of cellular
energy, in the form of ATP, are deeply involved in the
regulation of programmed cell death, in the homeostasis of
intracellular calcium, and are the site of several biosynthesis
pathways. Furthermore, they are the main source of reactive
oxygen species. Mitochondria derive from ancestral endo-
symbiont bacteria; as a reminiscence of such origin, they
contain several copies of a circular genome, the mtDNA,
which encodes key proteins of the oxidative phosphorylation
system. Like bacterial proteins, those synthetized within
mitochondria contains formyl-methionin, and their degrada-
tion origin chemotactic formyl peptides,1 which behave as
danger signals and can activate inflammasome.2 When cells
are coping with a massive insult that is potentially harmful for
the entire organism, mitochondria release into the cytoplasm
molecules able to trigger cell death, such as cytochrome-c or
apoptosis-inducing factor.
Mitochondria Contain and Release DAMPs
Although mitochondria are well known as key regulators of cell
death, in the last few years new roles as a component of
innate immune system have emerged. Mitochondria have
been shown to participate in intracellular signaling of retinoic
acid-inducible gene I-like receptors through engagement of
mitochondrial antiviral signaling protein, an adaptor protein
localized on the outer mitochondrial membrane,3 and to be
a source of DAMPs. DAMPs are conceptually similar to a
set of conserved molecules defined ‘pathogen-associated
molecular patterns’ (PAMPs). PAMPs are released by
several microorganisms and trigger a potent innate immune
response, causing inflammation through the engagement of
the same TLR that are bound by DAMPs. This novel,
expanding family includes hyaluronan fragments, heat shock
proteins, S100 proteins, amyloid-b, uric acid, interleukin
(IL)-1a, IL-33, and the DNA-binding nuclear protein ‘high
mobility group box 1’.4
In a pivotal paper, Zhang et al.5 studied patients who
survive a severe trauma, a condition that can origin a life-
threatening complication known as the ‘systemic inflamma-
tory response syndrome’ (SIRS), with shock and compro-
mised function of several organs. SIRS closely resembles
sepsis, and is due to DAMPs release into circulation. Zhang
et al.5 demonstrated that mtDNA and mtDNA-encoded formyl
peptides, collectively named mitochondrial DAMPs (MTDs),
are released by damaged tissues, and found in high amounts
in patients’ plasma. Formyl peptides bind the formyl peptide
receptor-1 (FPR-1), and mtDNA binds TLR-9, a receptor that
responds to bacterial or viral DNA as well as synthetic
oligodeoxynucleotides, containing unmethylated CpG motifs.
Activation of these receptors results in a potent inflammatory
reaction. Injecting in rats MTDs equivalent to 5% of the liver
resulted in a marked inflammation, with accumulation of
albumin and elastase in lungs, influx of inflammatory cells in
the airways, and appearance of tumor necrosis factor (TNF)-a
followed by IL-6. In vitro, clinical plasma concentrations of
mtDNA behave like GM-CSF in promoting the secretion of
IL-8 by neutrophils.
These results was further confirmed in patients undergoing
reamings of femur facture; bone tissue debris release MTDs in
plasma, which in turn cause lung injury by the release of
proinflammatory cytokines and neutrophil recruitment and
activation.6 In vitro studies show that triggering of such cells is
mediated by mtDNA through p38 MAPK intracellular phos-
phorylation, and can be inhibited by chloroquine,7 an inhibitor
of endosomal acidification, which is prerequisite for TLR-9
activation.8 Mitochondria-derived formyl peptides are able to
trigger oxidative burst and stimulate chemotaxis in neutrophils.9
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MTDs and HIV infection
The discovery of the inflammatory role of MTDs opens several
new perspectives. First, the quantification of MTDs in plasma
could become a marker of tissue injury, useful when a
massive cell death exists that has a pathogenetic role in
promoting or sustaining sterile inflammation, such as in the
case of autoimmune or cardiovascular diseases, chemo- and
radiotherapy of different tumors.
Second, MTDs can explain, at least partially, pathogenetic
mechanisms in different diseases. Several infections, such as
that provoked by HIV-1, are characterized by an important
immune activation. HIV-1 infects intestinal memory CD4þ
T cells causing their death and, as a consequence of decreased
immune defenses, that of intestinal cells. Profound functional
damages occur to mucosal surfaces, which lose their integrity
and allow the translocation of microbial products from the
intestinal lumen into the circulation. Then, cells of innate
immunity produce proinflammatory cytokines, causing activa-
tion and exhaustion of the immune system.
In this scenario antibiotics are quite ineffective, suggesting
the presence of other mechanisms. The release of MTDs by
damaged, apoptotic, or secondary necrotic cells could explain
persistent immune activation, which in turn causes the release
of MTDs from apoptotic immune cells and origins a vicious
circle. In the primate model of retroviral infection, cell
activation is crucial for the survival of the animal. Infected
sooty mangabeys display a low activation and survive; rhesus
macaques have a highly activate immune system and die of
AIDS. Studies on MTDs and their receptors could help in
understanding the genetic basis of such difference.
Few data are present on the role of soluble, plasma mtDNA
in subjects with viral or bacterial infections. Very recently, we
have measured plasma levels of mtDNA in different groups of
HIVþ patients: those experiencing an acute HIV infection
(AHI), long-term non progressors (LTNP), late presenters
(LP) taking antiretroviral therapy for the first time, and healthy
controls.10 In AHI and LP, mtDNA plasma levels were
significantly (410 times) higher than in healthy individuals
or in LTNP; plasma mtDNA levels were neither correlated to
peripheral blood CD4þ T cell count nor to markers of immune
activation, but had a significant correlation with plasma viral
load. Even if further studies are needed to confirm these
observations, it might be that we have identified a possible,
new role for mtDNA in the chronic inflammation that is typical
of HIV infection, or, eventually, that soluble, extracellular
mtDNA could be considered a new biomarker of virus-induced
damage. A hypothetical mechanism by which MTDs sustain
local inflammation and immune activation during HIV infection
is shown in Figure 1.
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Figure 1 A possible, hypothetical mechanism by which MTDs sustain local inflammation and generalized immune activation during HIV infection. This schematic cartoon
shows the hypothetical sequence of tissue damage caused by the release of MTDs during HIV-1 infection. Intestinal memory CD4þ T cells are infected by HIV-1 and,
because of the direct action of the virus or the cytotoxicity exerted by cytotoxic T cells (CTL), are damaged and undergo cell death (a). This causes alterations in mitochondria
that release MTDs, that is, mtDNA and formyl peptides that are products of the degradation of the proteins devoted to the synthesis of ATP by the process of oxidative
phosphorylation (OXPHOS). Changes in the capacity to cope with the intestinal flora impair the local immune defenses, and this ultimately cause a damage to intestinal cells (b),
with loss of the integrity of mucosal surfaces. MTDs released from damaged, apoptotic, necrotic, or secondary necrotic cells then bind their receptors on the surface of neutrophils;
in particular, formyl peptides bind the FPR-1, whereas mtDNA bindsTLR-9 (c). Activation of neutrophils causes either the release of proinflammatory cytokines or the migration of
these cells to the initial site of inflammation, with a further increase of the initial damage (d). Cytokines produced from neutrophils provoke a generalized activation of the immune
system (e), and finally activated lymphocytes can undergo cell death/apoptosis (f), release MTDs, and thus continue the vicious circle. (Drawings are not in scale)
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Concluding Remarks
Novel treatments could target either soluble MTDs or the
receptors they use. Little is known about the possibility to
block FPR-1 but molecules have been described that can
inhibit such receptor.11 Immunoregulatory DNA sequences
exist that bind and inhibit TLR-9.12 Molecules able to interfere
with TLR-9 such as the antimalaria drugs chloroquine,
hydrochloroquine, and quinacrine have been empirically used
for 60 years in the treatment of immune-mediated inflamma-
tory disorders, such as rheumatoid arthritis (RA), systemic
lupus erythematosus, and Sjo¨gren syndrome. The presence
of mtDNA in synovial fluid of patients with RA and its capability
act as proinflammatory molecule13 can explain the effects of
such drugs in this context. The benefic effects of chloroquine
that reduces the production/release of proinflammatory cyto-
kines have been described in viral infections14 and recently
confirmed in HIVþ patients;15 the well-known capability of
such molecule to act as an inhibitor of TLR activity8,16 can now
be viewed not only as a mechanism to block PAMPs triggering
of TLRs but also as a mechanism able to control DAMPs, and
particularly MTDs, stimulation of innate immune system.
In conclusion, in diseases characterized by excessive
inflammation, targeting FPR-1 and TLR-9 and/or interfering
with soluble MTDs could reduce harmful immune activation.
On the other hand, the use of MTDs for enhancing immune
responses has to be explored.
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